细胞淋巴瘤-话题@MedSci

#细胞淋巴瘤#

385篇内容 | 5207人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1702681, encodeId=4ba81e0268188, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性, objectType=article, longId=214110, objectId=d47e2141105c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d47e2141105c, replyNumber=0, likeNumber=80, createdTime=2022-06-13, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d47e2141105c, moduleTitle=J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d47e2141105c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702685, encodeId=9a2c1e02685d4, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=科普贴：外周T细胞淋巴瘤（PTCL）, objectType=article, longId=215397, objectId=3c8321539ee2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c8321539ee2, replyNumber=0, likeNumber=106, createdTime=2022-01-11, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c8321539ee2, moduleTitle=科普贴：外周T细胞淋巴瘤（PTCL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c8321539ee2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702662, encodeId=77c21e0266245, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤, objectType=article, longId=205805, objectId=fa1f20580549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa1f20580549, replyNumber=0, likeNumber=67, createdTime=2021-12-13, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa1f20580549, moduleTitle=FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa1f20580549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702680, encodeId=06531e02680c6, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=协和麒麟mogamulizumab单抗在中国递交上市申请，用于皮肤T细胞淋巴瘤, objectType=article, longId=213745, objectId=e743213e45ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e743213e45ef, replyNumber=0, likeNumber=66, createdTime=2022-02-24, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e743213e45ef, moduleTitle=协和麒麟mogamulizumab单抗在中国递交上市申请，用于皮肤T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e743213e45ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702669, encodeId=1be61e02669b5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Cancer Discov：Venetoclax+Navitoclax+化疗治疗复发/难治性急性淋巴细胞白血病和淋巴母细胞淋巴瘤, objectType=article, longId=207301, objectId=436420e30131, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=436420e30131, replyNumber=0, likeNumber=61, createdTime=2021-03-06, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=436420e30131, moduleTitle=Cancer Discov：Venetoclax+Navitoclax+化疗治疗复发/难治性急性淋巴细胞白血病和淋巴母细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=436420e30131)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702657, encodeId=db071e026578a, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤, objectType=article, longId=204048, objectId=2fa5204048fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fa5204048fb, replyNumber=0, likeNumber=50, createdTime=2021-03-30, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fa5204048fb, moduleTitle=Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fa5204048fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702678, encodeId=81241e02678c7, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Solasia宣布在日本提交抗癌药物DARINAPARSIN用于外周T细胞淋巴瘤的新药申请, objectType=article, longId=213648, objectId=33d021364893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33d021364893, replyNumber=0, likeNumber=120, createdTime=2022-03-24, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33d021364893, moduleTitle=Solasia宣布在日本提交抗癌药物DARINAPARSIN用于外周T细胞淋巴瘤的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33d021364893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702656, encodeId=643a1e02656d7, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=2020 CCO | 张清媛教授：外周T细胞淋巴瘤的治疗进展, objectType=article, longId=203797, objectId=5552203e971c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5552203e971c, replyNumber=0, likeNumber=123, createdTime=2021-11-11, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5552203e971c, moduleTitle=2020 CCO | 张清媛教授：外周T细胞淋巴瘤的治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5552203e971c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702648, encodeId=fd2f1e0264839, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：PD-1的免疫逃逸是富含T细胞/组织细胞的大B细胞淋巴瘤的定义特征, objectType=article, longId=200528, objectId=731c200528e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=731c200528e0, replyNumber=0, likeNumber=56, createdTime=2021-01-08, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=731c200528e0, moduleTitle=Blood：PD-1的免疫逃逸是富含T细胞/组织细胞的大B细胞淋巴瘤的定义特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=731c200528e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702650, encodeId=abf41e02650eb, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：20号染色体丢失是乳房植入物相关间变性大细胞淋巴瘤的特征, objectType=article, longId=201058, objectId=9098201058fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9098201058fe, replyNumber=0, likeNumber=99, createdTime=2020-11-17, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9098201058fe, moduleTitle=Blood：20号染色体丢失是乳房植入物相关间变性大细胞淋巴瘤的特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9098201058fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702645, encodeId=962b1e0264503, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：Avelumab治疗复发性/难治性结外NK/T细胞淋巴瘤, objectType=article, longId=199475, objectId=ce771994e50b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce771994e50b, replyNumber=0, likeNumber=62, createdTime=2020-11-05, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce771994e50b, moduleTitle=Blood：Avelumab治疗复发性/难治性结外NK/T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce771994e50b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702633, encodeId=c52a1e02633bd, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Bcl-2联合BTK抑制剂治疗慢性淋巴细胞淋巴瘤, objectType=article, longId=196296, objectId=7b82196296b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b82196296b4, replyNumber=0, likeNumber=109, createdTime=2020-11-06, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b82196296b4, moduleTitle=Bcl-2联合BTK抑制剂治疗慢性淋巴细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b82196296b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702665, encodeId=a93f1e0266577, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：皮质醇用的越多，采用CAR T细胞疗法治疗的大B细胞淋巴瘤患者的预后越差！, objectType=article, longId=206779, objectId=c005206e79a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c005206e79a5, replyNumber=0, likeNumber=87, createdTime=2021-04-23, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c005206e79a5, moduleTitle=Blood：皮质醇用的越多，采用CAR T细胞疗法治疗的大B细胞淋巴瘤患者的预后越差！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c005206e79a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702668, encodeId=5aae1e0266837, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期, objectType=article, longId=207011, objectId=dcad20e01104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcad20e01104, replyNumber=0, likeNumber=69, createdTime=2021-10-11, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcad20e01104, moduleTitle=JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcad20e01104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702630, encodeId=31541e0263090, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=ARCH PATHOL LAB MED：骨髓浸润的血管免疫母细胞淋巴瘤:识别和预后影响的组织学模式和诊断应用的辅助表型和分子分析, objectType=article, longId=195019, objectId=40ce19501978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ce19501978, replyNumber=0, likeNumber=55, createdTime=2020-12-25, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ce19501978, moduleTitle=ARCH PATHOL LAB MED：骨髓浸润的血管免疫母细胞淋巴瘤:识别和预后影响的组织学模式和诊断应用的辅助表型和分子分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ce19501978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702670, encodeId=b0c21e0267044, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle= Clinical Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关, objectType=article, longId=207556, objectId=3aa220e556bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aa220e556bc, replyNumber=0, likeNumber=72, createdTime=2021-09-05, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aa220e556bc, moduleTitle= Clinical Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3aa220e556bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702673, encodeId=8e0c1e0267323, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：血管内大B细胞淋巴瘤的遗传特征, objectType=article, longId=208781, objectId=48ff208e81d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48ff208e81d8, replyNumber=0, likeNumber=69, createdTime=2022-02-25, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48ff208e81d8, moduleTitle=Blood：血管内大B细胞淋巴瘤的遗传特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48ff208e81d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702627, encodeId=46ff1e0262739, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris, objectType=article, longId=194236, objectId=13fa194236c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13fa194236c3, replyNumber=0, likeNumber=64, createdTime=2021-01-28, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13fa194236c3, moduleTitle=欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13fa194236c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702634, encodeId=db191e02634ce, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO, objectType=article, longId=196393, objectId=d7b919639342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7b919639342, replyNumber=0, likeNumber=77, createdTime=2021-03-16, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7b919639342, moduleTitle=FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7b919639342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702647, encodeId=67d81e02647cc, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet：Liso-cel治疗复发性/难治性大B细胞淋巴瘤活性好、安全性高, objectType=article, longId=200150, objectId=af16200150b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af16200150b6, replyNumber=0, likeNumber=66, createdTime=2021-07-24, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af16200150b6, moduleTitle=Lancet：Liso-cel治疗复发性/难治性大B细胞淋巴瘤活性好、安全性高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af16200150b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

细胞淋巴瘤

2020-05-29

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性

2022-06-13

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

科普贴：外周T细胞淋巴瘤（PTCL）

2022-01-11

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤

2021-12-13

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

协和麒麟mogamulizumab单抗在中国递交上市申请，用于皮肤T细胞淋巴瘤

2022-02-24

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Cancer Discov：Venetoclax+Navitoclax+化疗治疗复发/难治性急性淋巴细胞白血病和淋巴母细胞淋巴瘤

2021-03-06

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤

2021-03-30

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Solasia宣布在日本提交抗癌药物DARINAPARSIN用于外周T细胞淋巴瘤的新药申请

2022-03-24

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

2020 CCO | 张清媛教授：外周T细胞淋巴瘤的治疗进展

2021-11-11

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：PD-1的免疫逃逸是富含T细胞/组织细胞的大B细胞淋巴瘤的定义特征

2021-01-08

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：20号染色体丢失是乳房植入物相关间变性大细胞淋巴瘤的特征

2020-11-17

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：Avelumab治疗复发性/难治性结外NK/T细胞淋巴瘤

2020-11-05

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Bcl-2联合BTK抑制剂治疗慢性淋巴细胞淋巴瘤

2020-11-06

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：皮质醇用的越多，采用CAR T细胞疗法治疗的大B细胞淋巴瘤患者的预后越差！

2021-04-23

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期

2021-10-11

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

ARCH PATHOL LAB MED：骨髓浸润的血管免疫母细胞淋巴瘤:识别和预后影响的组织学模式和诊断应用的辅助表型和分子分析

2020-12-25

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Clinical Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关

2021-09-05

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：血管内大B细胞淋巴瘤的遗传特征

2022-02-25

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris

2021-01-28

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO

2021-03-16

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Lancet：Liso-cel治疗复发性/难治性大B细胞淋巴瘤活性好、安全性高

2021-07-24

科室
- - 订阅+
  - 更多科室
工具
服务